P15. Crizotinib in metastatic ALK-positive lung cancer—results from clinical practice in Slovakia

Background Crizotinib was approved and authorized for use in the European Union in October 2012. Since then crizotinib has been available in Slovakia for treatment of advanced metastatic non-small cell lung cancer (NSCLC) after failure of standard chemotherapy only, based on the wording of the therapeutic indications by the European Medicines Agency. Purpose of this study was to assess results achieved with crizotinib in the treatment of advanced, metastatic NSCLC in clinical practice in Slovakia.